Jefferies & Co. has a Hold rating and a $3.50 price target on shares of Avanir Pharmaceuticals AVNR.
In the note, Jefferies writes, "Notice of a Paragraph IV certification challenging AVNR's Nuedexta appeared on the FDA website on 6/30. While we had been anticipating a Paragraph IV challenge, we think the submission date of 3/7 was notable, since AVNR only officially began promoting Nuedexta on 2/7, following its approval on 10/29."
At last check, shares of AVNR were up 1 cent to $3.37.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in